Paste.InterGen.Online

Anti-obesity drugs Market Key Highlights and Fut

From Roots, 2 Months ago, written in Plain Text, viewed 23 times.
URL https://paste.intergen.online/view/0fd40389 Embed
Download Paste or View Raw
  1. Anti-obesity Drugs Market Size to Hit USD 104.9 Billion by 2035 | Exclusive Report by Roots Analysis
  2.  
  3. The anti-obesity drugs market, valued at USD 12.8 billion in 2024, is projected to grow to USD 19.6 billion in 2025 and USD 104.9 billion by 2035, representing a CAGR of 18.3% during the forecast period.
  4.  
  5.  
  6. Link: https://www.rootsanalysis.com/reports/anti-obesity-drugs-market.html
  7. Anti-obesity drugs consist of various pharmaceutical treatments aimed at helping individuals manage obesity and related health issues. These medications provide healthcare professionals with valuable tools to complement lifestyle interventions, such as diet and exercise. They play a critical role in enhancing weight loss outcomes, particularly for patients with significant obesity-related comorbidities. Further, these drugs contribute to improved quality of life and potentially lower healthcare costs by preventing complications associated with obesity. Advancements in drug formulation and delivery systems, along with the integration of novel compounds, have led to the emergence of more effective and safer anti-obesity medications. The increasing focus on personalized medicine and pharmacogenomics further enhances the potential for tailored treatments that address individual patient needs. Additionally, the surge in telehealth services and digital therapeutics applications is facilitating better patient engagement and adherence to treatment regimens.
  8.  
  9. Anti-obesity Drugs Market Segments
  10.  
  11. Based on the type of molecule, the market is segmented into biologics and small molecules
  12.  
  13.      The small molecules segment is likely to capture the largest revenue share of around 55% in the anti-obesity drugs market in 2024.
  14.      The biologics segment is anticipated to be the fastest growing segment in this industry, with an annualized growth rate (CAGR) of 23.8%, during the forecast period.
  15.  
  16. Based on the active compound used, the market is segmented into tirzepatide, semaglutide, retatrutide, survodutide, cagrilintide and semaglutide, orforglipron, liraglutide, other active compounds
  17.  
  18.      The semaglutide segment is likely to capture the largest revenue share of around 55% in the anti-obesity drugs market in 2024.
  19.      The tirzepatide segment is anticipated to be the fastest growing segment in this industry, with an annualized growth rate (CAGR) of 18.3%, during the forecast period.
  20.  
  21. Based on the mechanism of action, the market is segmented into GLP-1 agonists / GIP agonists, GLP-1 agonists / GCGR agonists, GLP-1 agonists, GLP-1 agonists / Amylin analogues, GLP-1 / GCGR / GIP agonists and other mechanisms of action
  22.  
  23.      The GLP-1 agonists segment is likely to capture the largest revenue share of 65% in the anti-obesity drugs market in 2024.
  24.      The GLP-1 agonists / GIP agonists segment is anticipated to be the fastest growing segment in this industry, with an annualized growth rate (CAGR) of 21.1%, during the forecast period.
  25.  
  26. Based on the type of agonist, the market is segmented into single-agonists, dual-agonists and tri-agonists
  27.  
  28.      The single-agonists segment is likely to capture the largest revenue share of around 70% in the anti-obesity drugs market in 2024.
  29.      The dual-agonists segment is anticipated to be the fastest growing segment in this industry, with an annualized growth rate (CAGR) of 25.7%, during the forecast period.
  30.  
  31. Based on the action pathway, the market is segmented into centrally acting, peripherally acting, centrally acting and peripherally acting drugs
  32.  
  33.      The centrally acting drugs segment is likely to capture the largest revenue share of around 85% in the anti-obesity drugs market in 2024.
  34.      The centrally acting drugs segment is anticipated to be the fastest growing segment in this industry, with an annualized growth rate (CAGR) of 22.6%, during the forecast period.
  35.  
  36. Based on the route of administration, the market is segmented into oral and parenteral route of administration  
  37.  
  38.      The segment for parenteral route of administration is likely to capture the largest revenue share of more than 95% in the anti-obesity drugs market in 2024.
  39.      The segment for oral route of administration is anticipated to be the fastest growing segment in this industry, with an annualized growth rate (CAGR) of 40.6%, during the forecast period.
  40.  
  41. Based on the regional insights, the market is segmented into North America, Europe, Asia-Pacific and Latin America
  42.  
  43.      North America is likely to dominate the anti-obesity drugs market, by capturing the largest revenue share of nearly 70%, in 2024.
  44.      In Asia-Pacific, the anti-obesity drugs market is likely to demonstrate considerable growth with a relatively higher CAGR (~40%) during the forecast period.
  45.  
  46.  
  47. Anti-obesity Drugs Market Regional Outlook
  48.  
  49. Based on the geographical regions, the anti-obesity drugs market can be segmented into four major regions, North America, Europe, Asia-Pacific and Latin America. Led by the US, North America is anticipated to capture the majority share of the anti-obesity drugs market in 2024. Further, the weight loss industry in Asia-Pacific is accounted to be the fastest-growing segment of the market. This is primarily due to the increased awareness and acceptance of obesity as a chronic disease in the region.
  50.  
  51.  
  52. Key Market Players
  53.      Adocia
  54.      AstraZeneca
  55.      Boehringer Ingelheim
  56.      CinFina Pharma
  57.      Eli Lilly
  58.      Gmax Biopharma
  59.      Hanmi Pharm
  60.      Jiangsu Hengrui Pharmaceuticals
  61.      Kallyope
  62.      Novo Nordisk
  63.      PegBio
  64.      Pfizer
  65.      QL Biopharm
  66.      Regeneron
  67.      Roche
  68.      Sciwind Biosciences
  69.      Viking Therapeutics
  70.      Zealand Pharma
  71.  
  72. Anti-obesity Drugs Market Segments
  73.  
  74. Anti-obesity Drugs Market, by Type of Molecule
  75.      Biologics
  76.      Small Molecules
  77.  
  78. Anti-obesity Drugs Market, by Active Compound Used
  79.      Tirzepatide
  80.      Semaglutide
  81.      Retatrutide
  82.      Survodutide
  83.      Cagrilintide and Semaglutide
  84.      Orforglipron
  85.      Liraglutide
  86.      Other Active Compounds
  87.  
  88. Anti-obesity Drugs Market, by Mechanism of Action
  89.      GLP-1 Agonist / GIP Agonist
  90.      GLP-1 Agonist / GCGR Agonist
  91.      GLP-1 Agonist
  92.      GLP-1 Agonist / Amylin Analogue
  93.      GLP-1 / GCGR / GIP Agonist
  94.      Other Mechanisms of Action
  95.  
  96. Anti-obesity Drugs Market, by Type of Agonist
  97.      Single-Agonist
  98.      Dual-Agonist
  99.      Tri-Agonist
  100.  
  101. Anti-obesity Drugs Market, by Action Pathway
  102.      Centrally Acting
  103.      Peripherally Acting
  104.      Centrally Acting and Peripherally Acting
  105.  
  106. Anti-obesity Drugs Market, by Route of Administration
  107.      Oral
  108.      Parenteral
  109.  
  110. Anti-obesity Drugs Market, by Geographical Regions
  111.      North America
  112.      Europe
  113.      Asia-Pacific
  114.      Latin America
  115.  
  116.  
  117. About Roots Analysis
  118. About Roots Analysis**
  119. Roots Analysis is a global research and consulting powerhouse specializing in Healthcare, Pharmaceutical, Biotech, Semiconductors, Chemicals and ICT industry. With over a decade of experience, they’ve supported more than 750 clients — spanning Fortune 500 companies, innovative startups, academic institutions, VCs, and strategic investors.
  120.  
  121. **Why Use Roots Analysis in era of Artificial Intelligence?**
  122. 1.      Tailored Insights
  123. 2.      Robust Methodology
  124. 3.      Smart Decisions Made Easy
  125. By combining world-class domain expertise, careful data gathering, and dialogue with senior industry experts, Roots Analysis ensures their deliveries are trustworthy, actionable, and aligned with strategic priorities. The value proposition generated on insights generated by Roots Analysis team is unparalleled in the market research industry.
  126.  
  127. **Services Offered:**
  128. 1.      Consulting Services (custom insights supporting strategic and tactical requirements, off-the-shelf ready to consume work)
  129. Roots Analysis offers bespoke consulting services tailored to the unique needs of clients in the life sciences and healthcare sectors.
  130.  
  131. They specialize in market assessments, tracking industry trends, dynamics, and competitive positioning. These insights help companies fine-tune their product strategies and market-entry plans.
  132.  
  133. Roots Analysis also delivers expert guidance on partnerships, licensing, and investment opportunities. Their strategic support extends to KOL identification, publication analysis, and regulatory intelligence, making them a valuable partner in business growth and innovation.
  134.  
  135. 2.      Subscription Services (bundled services supporting multiple topics and domains for a firm)
  136.  
  137. With their subscription plans, Roots Analysis provides seamless access to a vast library of market intelligence reports. Subscribers enjoy unlimited downloads in multiple formats.
  138.  
  139. The service includes on-demand research support—allowing clients to request tailored insights and initiate custom research topics. This ensures that emerging needs are met quickly and effectively.
  140.  
  141. Each subscription comes with a dedicated account manager and direct access to analysts. Flexible billing options and tiered plans make this service suitable for organizations of all sizes seeking continuous, reliable insights.
  142.  
  143. **Contact Details for Roots Analysis**
  144. Chief Executive:  Gaurav Chaudhary
  145. Email:  Gaurav.chaudhary@rootsanalysis.com
  146. Website: https://www.rootsanalysis.com/
  147.  
  148.  

Reply to "Anti-obesity drugs Market Key Highlights and Fut"

Here you can reply to the paste above

Powered by Stikked